Pasithea Therapeutics Cor... (KTTA)
The price, the headline numbers and the latest news, in one place.
Pasithea Therapeutics Corp. (KTTA) Stock Price, Analysis & Data
| Bid | 0.39 |
| Market Cap | 18.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.29M |
| 0.29 | |
| -1.35 | |
| n/a | |
| -1.22 | |
| P/B (ttm) | 0.38 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 0.72 |
| Volume | 483,905 |
| Avg. Volume (20D) | 736,273 |
| Open | 0.57 |
| Previous Close | 0.55 |
| Day's Range | 0.54 - 0.60 |
| 52-Week Range | 0.28 - 2.06 |
| Analyst | Strong Buy |
| Price Target | 3 (435.71%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KTTA
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and B...
Financial Performance
In 2025, Pasithea Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -20.43M, an increase of 46.91%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for KTTA stock is "Strong Buy". The 12-month stock price forecast is 3, which is upside of 435.71% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.16 misses estimates by 0.00, with 93.52% YoY growth.
